AstraZeneca Pharma India Limited filed its Business Responsibility and Sustainability Report for the financial year 2025-26, disclosing a total turnover of ₹22,755.8 million. The company reported that manufacturing activities at its sole plant were ceased during the year under review. The filing, submitted to the BSE Limited and National Stock Exchange of India Limited, includes an Independent Practitioners’ Limited Assurance Report provided by KPMG Assurance and Consulting Services LLP.

Financial and Operational Overview

The company’s paid-up capital stands at INR 50,000,000. For the financial year 2025-26, export sales contributed ₹1,175.6 million, accounting for 5.2% of the total turnover. The entity operates primarily in the pharmaceuticals sector, with marketing and trading of pharmaceutical products accounting for 90% of its standalone turnover. The reporting boundary for the BRSR is on a standalone basis.

Employee Statistics

As of the end of the financial year, AstraZeneca Pharma India Limited employed 760 permanent employees, comprising 558 male and 202 female workers. The company reported no permanent workers or other than permanent employees on its rolls. The representation of women on the Board of Directors was 83.33%, while women constituted 66.7% of the Key Management Personnel.

Employee Composition

Sustainability and Environmental Impact

The report details the company’s environmental performance, noting that the manufacturing facility underwent decommissioning during the reporting period. Consequently, the company stated it had no specific projects related to reducing greenhouse gas emissions during the year. However, the company maintained mechanisms for Zero Liquid Discharge, where generated effluent is 100% treated in-house and used for landscaping. The organisation confirmed compliance with applicable environmental laws, including conditions from the Karnataka State Pollution Control Board.

Governance and Assurance

The Business Responsibility and Sustainability Report was approved by the Board and covers all nine principles of the National Guidelines on Responsible Business Conduct. Mr. Praveen Rao Akkinepally, Managing Director, oversees the Business Responsibility and Sustainability initiatives. The company obtained limited assurance on the BRSR Core Indicators from KPMG Assurance and Consulting Services LLP.

AstraZeneca Pharma has secured approval from the Central Drugs Standard Control Organisation (CDSCO) to import and sell Benralizumab for the treatment of Hypereosinophilic Syndrome (HES) in patients aged 12 and above. This regulatory clearance represents a notable development for the company's product portfolio in India, enabling access to this therapy for a broader patient population.

Regulatory Approval Details

The CDSCO approval specifically covers the import and commercial sale of Benralizumab indicated for Hypereosinophilic Syndrome. The approval is applicable for patients aged 12 years and above, extending the drug's availability to both adolescent and adult patient groups within India.

Significance of the Approval

Hypereosinophilic Syndrome is a rare condition characterised by persistently elevated eosinophil levels, which can lead to damage to multiple organs. The CDSCO nod for Benralizumab in this indication provides a targeted therapeutic option for patients in India who meet the specified age criteria. This approval underscores AstraZeneca Pharma's continued engagement with Indian regulatory authorities to expand the availability of specialised medicines in the country.